Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticbreast cancersubjects withpriorcapecitabine
  Phrases that lowered it: objective20safetylabelpharmacokinetic
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: sequential (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Number of arms: 7 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 8 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 26.5% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Keywords listed: 9 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 7 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ NCT02593708 · started 2015 · scored riskier than 36% of active trials terminated
• Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer NCT01423123 · started 2011 · scored riskier than 91% of active trials completed
• Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer NCT01111825 · started 2010 · scored riskier than 88% of active trials completed
• Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer NCT01827267 · started 2013 · scored riskier than 84% of active trials completed
• A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor NCT01128842 · started 2010 · scored riskier than 52% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.